Enhancer-targeting further improves the efficacy of BCR::ABL1 kinase inhibitors used for Ph+B-ALL therapy, especially in cells from IKZF1<sup>PLUS</sup> patients that most frequently relapse from current treatment, suggesting enhancer-targeting as a potential promising addition to current therapy. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.